NM Gavryliuk¹, ІYa Hospodarskii¹*, OV Prokopchuk¹, ОV Bushtynska¹, MYe Havrylyuk² and OA Kozak¹

¹Department of Higher Nursing Education, Patient Care and Clinical Immunology, I. Horbachevsky Ternopil National Medical University, Ukraine

²Department of Internal Medicine No.1, I. Horbachevsky Ternopil National Medical University, Ukraine

*Corresponding Author: ІYa Hospodarskii, Department of Higher Nursing Education, Patient Care and Clinical Immunology, I. Horbachevsky Ternopil National Medical University, Ukraine.

Received: November 30, 2021; Published: December 23, 2021

Abstract

Liver fibrosis is a significant medical and economic problem in many countries, particularly developed ones, with excess incidence of overweight and obesity, as well as in the countries with high incidence of viral hepatitis. Taking into account the significant progress in the molecular understanding of liver fibrosis, the problem of early diagnostics, disease course prediction and search for effective pathogenetically substantiated approaches to its treatment remains important. The presented article highlights the main methods of posthepatitis liver fibrosis diagnostics after elimination of viral hepatitis type C and in patients with non-alcoholic fatty liver disease affected by overweight and obesity by evaluating fibrosis serum markers. Authors highlighted connections with non-alcoholic fatty liver disease, posthepatitis liver fibrosis after elimination of viral hepatitis type C in patients with overweight and obesity, perspective directions for the use of these data are also formulated.

KeywordsPosthepatic Fibrosis; NAFLD; Overweight; FibroTest; FIB-4; TGF-β1

References

1. Marcellin Patrick and Blaise K Kutala. “Liver diseases: A major, neglected global public health problem requiring urgent actions and large-scale screening”. Liver International: Official Journal of the International Association for the Study of the Liver1 (2018): 2-6.
2. Poilil Surendran Suchithra., et al. “Nanoparticles for the treatment of liver fibrosis”. International Journal of Nanomedicine 12 (2017): 6997-7006.
3. Koyama Yukinori and David A Brenner. “Liver inflammation and fibrosis”. The Journal of Clinical Investigation1 (2017): 55-64.
4. Trautwein C., et al. “Hepatic fibrosis: Concept to treatment”. Journal of Hepatology1 (2015): S15-24.
5. Anokhina GA., et al. “The role of and metabolic disorders in recent diseases: prevention and treatment”. Health of Ukraine: Medical Newspaper 15-16 (2018): 60-62.
6. Chan Y T., et al. “Targeting Hepatic Stellate Cells for the Treatment of Liver Fibrosis by Natural Products: Is It the Dawning of a New Era”. Frontiers in Pharmacology 11 (2020): 548.
7. Polyzos S A., et al. “Obesity and nonalcoholic fatty liver disease: From pathophysiology to therapeutics”. Metabolism: Clinical and Experimental 92 (2019): 82-97.
8. Takahashi Y., et al. “Non-alcoholic fatty liver disease fibrosis score and FIB-4 scoring system could identify patients at risk of systemic complications”. Hepatology Research: The Official Journal of the Japan Society of Hepatology6 (2015): 667-675.
9. Yefimenko T and Mykytyuk M. “Non-Alcoholic Fatty Liver Disease: Time for Changes”. International Journal of Endocrinology (Ukraine)4 (2021): 334-345.
10. Vakalyuk II and Virstyuk NG. "Relationship of the liver fibrous formation processes and cardiosclerosis in patients with stable coronary heart disease combined with non-alcoholic fatty liver disease". Klin Med 2 (2018): 168-173.

Citation

Citation: ІYa Hospodarskii., et al. “The Results of Serum Markers of Liver Fibrosis in Patients with Posthepatic Fibrosis and in Patients with Non-alcoholic Fatty Liver Disease Depending on Body Weight". Acta Scientific Gastrointestinal Disorders 5.1 (2022): 36-40.

Copyright

Copyright: © 2022 ІYa Hospodarskii., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.